In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Molecular Diagnostics M&A: Dormant But Not Done

Executive Summary

The current crop of molecular diagnostics acquisitions – espcially those made by nontraditional buyers – must mature prior to the commencement of additional M&A activity. Historical data suggest this could occur starting in the 2014-2015 timeframe.


Related Content

Matchmaking And Integration In The New World Of Diagnostics M&A
Device Trends To Watch In 2013
Trends In Diagnostics – 2012
Hologic Grabs Gen-Probe
Genomics Through The Lens Of Precompetitive Data Sharing
What's Fueling The Recent Diagnostics Dealmaking?
With Genoptix, Novartis Continues Its Diagnostics Build-up
The How And When Of Applying Sequencing To Clinical Diagnostics


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts